Intrinsic or acquired resistance to docetaxel is common in mCPRC patients and the response to docetaxel is highly variable. In view of the ongoing debate about the best treatment sequence strategy for mCRPC and the novel approach of using docetaxel in hormone naïve patients, insight into factors that influence interpatient variability and mechanisms of taxane resistance is crucial.

R. de Wit (Ronald) , W.M. van Weerden (Wytske)
Erasmus University Rotterdam
Department of Urology

de Morrée, E. (2016, September 7). Preclinical and Clinical Aspects of Taxane Responsiveness and Sensitivity in Castration Resistant Prostate Cancer. Retrieved from